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ABSTRACT 
MDMA (‘ecstasy’) tablets are widely used recreationally, and not only vary in their 
appearance, but also in MDMA content. Recently, the prevalence of high-content tablets 
is of concern to public health authorities.  
To compare UK data with other countries, we have evaluated MDMA content of 412 
tablets collected from the UK, 2001-2018, and have investigated within-batch content 
variability for a sub-set of these samples. In addition, we have investigated dissolution 
profiles of tablets using pharmaceutical industry-standard dissolution experiments on 247 
tablets. All analyses were carried out using LC-MS/MS.  
Our data supported other studies, in that recent samples (2016 – 2018) tend to have 
higher MDMA content compared to earlier years. In 2018, the median MDMA content 
exceeded 100 mg free-base for the first time. Dramatic within-batch content variability 
(up to 136 mg difference) was also demonstrated. Statistical evaluation of dissolution 
profiles at 15-minutes allowed tablets to be categorised as fast-, intermediate-, or slow-
releasing, but no tablet characteristics correlated with dissolution classification. Hence, 
there would be no way of users knowing a priori whether a tablet is more likely to be fast 
or slow-releasing. Further, within-batch variation in dissolution rate was observed. 
Rapid assessment of MDMA content alone provides important data for harm reduction, 
but does not account for variability in (i) the remainder of tablets in a batch, nor (ii) MDMA 
dissolution profiles. Clinical manifestations of MDMA toxicity, especially for high-content, 
slow-releasing tablets, may be delayed or prolonged, and there is a significant risk of users 
re-dosing if absorption is delayed.     
KEYWORDS 
Ecstasy, MDMA, 3,4-methylenedioxymetamfetamine, dissolution, public health 
  
  
Variability in dissolution profiles of MDMA tablets 
Couchman L, et al 
Page 3 of 18 
1 INTRODUCTION 
3,4-Methylenedioxymetamfetamine (MDMA, ‘ecstasy’) is a common recreational drug, 
and is particularly popular amongst nightclub and music festival attendees due to the 
empathogenic/entactogenic nature of the MDMA ‘high’1. Use is typically associated with 
younger populations. One study in the UK of 482 education centres found approximately 
one fifth (18.9 %) of the adolescents (16-21 years) questioned had at some time used 
MDMA2. In England and Wales in 2017, there were 56 deaths attributed to MDMA 
toxicity3. 
An additional consideration more recently is the availability of MDMA via the Darknet, 
purchased using cryptocurrencies, of which there are many4,5. There is some evidence 
that the perception amongst users is that drugs bought via the Darknet are (i) more likely 
to be ‘as advertised’, i.e. not containing an entirely different compound or not adulterated 
with other compounds and (ii) of higher content6-8. Though limited and not necessarily 
representative of the global marketplace, evidence available from the Netherlands 
suggests that MDMA tablets bought on-line are of a statistically significant, but only 
slightly higher content, than those bought on the street (131 and 121 mg, respectively)8. 
Current concerns for risks posed to recreational ecstasy users focusses on the prevalence 
of high-content MDMA tablets. Tablets containing 200-300 mg MDMA have been 
reported, including some tablets which had clearly been produced for sale at specific 
events, bearing the event logo9. 
That users may be actively seeking means to ensure the MDMA content of the drugs they 
are buying is some evidence for the problem which exists regarding variability in drug 
dosage. Indeed, a number of ‘home-testing’ kits, typically using Marquis reagent or similar 
colour tests, are now commercially available10,11. Furthermore, variability in MDMA 
dosage (for tablets) and purity (for ‘crystals’) has previously been reported by a number 
of groups9,12-20, including a study previously carried out by this group for a sample of 
MDMA tablets collected in the UK in 200621, which showed wide variability in the MDMA 
content of tablets in the UK [(range 20 – 131 mg MDMA hydrochloride per tablet (16.8 – 
110 mg MDMA free-base)].  
Dissolution testing is commonplace in the quality control and batch production of drugs 
in pharmaceutical laboratories, and for bioequivalence testing when developing new 
formulations or generic versions of existing drugs22,23. Standard protocols are available22.  
During drug and formulation development, dissolution data are used to determine 
pharmacokinetic parameters and guide decisions on dose frequency. Such data for illicit 
drugs are, unsurprisingly, sparse but are potentially of value for policy-makers and for 
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informing harm reduction strategies. Notwithstanding the known problem of MDMA 
content variability, two MDMA tablets with markedly different dissolution profiles could 
pose significantly different clinical risks to users.  
In this study, we have analysed MDMA tablets collected in the UK using liquid 
chromatography with tandem mass-spectrometry (LC-MS/MS). We have analysed 
representative samples from 2001 – 2018 to quantify MDMA content, including 
quantification for multiple tablets within a ‘batch’ to assess within-batch content 
variability. The study aims to update our previous study with more recent MDMA tablets, 
examine these data longitudinally, and to see how the UK data compare to those collected 
in Spain and Portugal24. In addition, we have taken a sub-set of MDMA tablets and, for 
the first time to our knowledge, report data from dissolution studies to demonstrate 
variability in MDMA tablet dissolution. 
2 METHODS 
2.1 CHEMICALS AND REAGENTS 
MDMA and MDMA-D5 certified reference solutions (1 g/L and 100 mg/L in acetonitrile, 
respectively), MDMA hydrochloride reference standard, hydrochloric acid and formic acid 
were all from Sigma Aldrich (Poole, UK). LC-MS grade methanol was from Rathburn 
(Walkerburn, Scotland, UK). Isopropanol was from VWR (Lutterworth, UK). Water was 
deionised in-house (> 18 megohm cm, Elix®, Watford, UK). 
2.2 MDMA TABLETS AND CRYSTALS 
Tablets analysed were those collected from amnesty bins, or seized during entry searches, 
from a number of large music festivals and nightclubs in the UK. All were initially identified 
as potentially containing MDMA by visual identification, based on size, shape, colour and 
markings/logos, to tablets found to have contained MDMA previously. (TICTAC visual drug 
identification and information system for solid dose drugs, version 23.1, TICTAC 
Communications Ltd., London, UK)25. All TICTAC database entries were confirmed by gas 
chromatography mass-spectrometry (GC-MS) analysis (7890-5975C, Agilent Technologies, 
Santa Clara, CA). All tablets were stored in sealed 7 mL glass sample containers (VWR, 
Lutterworth, UK) at room temperature (nominally 20 to 25 °C). Only whole tablets were 
included in the analysis, i.e. any damaged tablets, or those with obvious fragments 
missing were excluded from the study. 
For MDMA content measurement, a total of 412 tablets were analysed. Included were 
249 single tablets from different sources, and 45 ‘batches’ of tablets (i.e. multiple tablets 
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from the same source, between 2 and 8 tablets per batch, total 163 tablets). The latter 
were used to assess within-batch variability in MDMA content. In addition, a subset of 
these samples (N = 34, 2004 – 2017) were identified by TICTAC as containing a variety of 
additional, non-MDMA, compounds. For dissolution testing, 247 tablets (98 single tablets 
from different sources, and 61 batches of tablets – between 2 and 9 tablets per batch, as 
well as 6 crystal samples were analysed, 3 as ‘bombs’ wrapped in cigarette paper, and 3 
as loose crystals). Although MDMA is usually present in ‘street’ samples as the 
hydrochloride salt, we express our findings as MDMA free-base as we did not determine 
which salt was present in the samples. 
2.3 MDMA CONTENT MEASUREMENT 
Tablets were crushed and homogenised using a clean agate pestle and mortar, and the 
crushed tablets were stored in glass sample containers at room temperature. For analysis, 
approximately 10 mg of tablet was weighed accurately (AE240, Mettler Toledo, Leicester, 
UK), and the weighed powder transferred to a 100 mL volumetric flask, which was made 
to volume with a solution of 50 % (v/v) methanol in deionised water. After thorough 
mixing by inversion (30 min), 1 mL portions were diluted (1+9, v/v) with 50 % (v/v) 
methanol in deionised water and were stored refrigerated (2 – 8 C) in 15 mL screw-cap 
tubes (Sarstedt, Leicester, UK) prior to analysis. MDMA calibrators (N = 6, 2 mL each 
calibration level) were prepared by dilution of MDMA stock solution (1 g/L) over the range 
0.50 – 100 mg/L in 50 % (v/v) methanol in deionised water. 
For analysis, prepared samples and calibrators (50 µL) were diluted with MDMA-D5 
solution (10 mg/L, 50 µL) in 1.5 mL micro-centrifuge tubes and 0.1 % (v/v) formic acid in 
deionised water (900 µL). Portions of these mixtures (20 µL) were diluted further with 
0.1 % (v/v) formic acid in deionised water (380 µL) directly into 96-well plates with 
eluent A, 0.1 % (v/v) formic acid in deionised water. Diluted samples (2 µL) were injected 
onto a reversed-phase (C18), tapered-bore column (2.7 µm, 25 x 2.0–0.5 mm i.d., 
WarpLCMS, Penn Valley, CA) and analysed using gradient elution (Table S1) on an 
Acquity™ LC instrument (Waters, Manchester, UK). Analytes were monitored using a 
TQD MS (Waters, Manchester, UK), operating in positive electrospray ionisation, multiple 
reaction monitoring (MRM) mode. Ion transitions (collision energy, V) were: m/z 194.1 to 
104.9 (24) and 163.0 (12), and 199.2 to 107.0 (26) and 165.0 (12) for MDMA and MDMA-
D5, respectively. The dwell time for each MRM transition was 25 ms. Ionisation source 
conditions were: capillary voltage 0.5 kV, cone voltage 3 V, extractor voltage 3 V, source 
temperature 150 ⁰C, desolvation gas temperature 450 ⁰C, and desolvation gas flow rate 
900 L/h. Data were analysed using MassLynx™ (version 4.1) and Microsoft Excel (2016 
version).  
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For external quality control (EQC) to assess the method accuracy, portions of crushed 
MDMA tablets (N = 10) covering a range of MDMA content were sent to a second 
laboratory (LGC, Teddington, UK) for analysis. These were analysed by LGC without 
knowledge of the results obtained at ASI. The LGC results (MDMA content, as free-base, 
per tablet) were compared against those obtained by ASI. For internal quality control 
(IQC) and to assess between-assay precision, a selection of tablets (N = 3 of the 10 samples 
chosen for EQC) were chosen and were analysed with each of the batches. 
For the tablets which were expected to contain additional compounds, extracted tablets 
were analysed using an LC-MS/MS method containing MRM transitions for > 100 drugs 
and metabolites (2 MRM transitions per analyte, 12-minute gradient elution), used in our 
laboratory for routine forensic toxicology investigations. 
2.4 DISSOLUTION TESTING 
A 7-vessel dissolution bath (Pharma Test DT70, Hainburg, Germany) was used. Dissolution 
solvent (900 mL per vessel) was 0.05 mol/L aqueous hydrochloric acid. Bath temperature 
was maintained at 37 ± 0.5 °C, and the stirrer rate was 50 rpm. Samples (5 mL) were taken 
using a volumetric syringe via the sampling line and filter before addition of the tablet (t0), 
and subsequently after 5, 10, 15, 20, 30, 45, 60, 90, and 120 minutes. A final sample was 
drawn at 180 minutes (stirrer rate increased to 150 rpm for the final 60 minutes). After 
each sample was drawn, the solution was replaced with 5 mL blank dissolution solution 
to maintain the vessel volume. Samples drawn at each time point were collected into 15 
mL screw-cap tubes and stored at 2 – 8 C prior to analysis.  
To confirm the stability of MDMA in the dissolution solution at for the 180-minute 
duration of the experiment,  a solution of MDMA (0.1 mg/L, prepared in the dissolution 
solution) was incubated at 37 C and samples were drawn and analysed at each of the 
planned time points. This experiment also tested for any loss of analyte in the dissolution 
bath system (e.g. via adsorption to the vessel or syringe filter). 
As for the content measurement, MDMA calibrators (N = 6, 2 mL each calibration level) 
were prepared by dilution of certified MDMA reference solution (1 g/L), this time over 
the range 0.50 – 200 mg/L in 50 % (v/v) methanol in deionised water. In addition, internal 
quality control (IQC) solutions were independently prepared from MDMA hydrochloride 
at 100, 10.0 and 1.00 mg/L (84.8, 8.48 and 0.85 mg/L MDMA free-base, respectively) in 
50 % (v/v) methanol in deionised water. 
For analysis of the collected samples, portions of the sample (10 µL) were mixed with 
MDMA-D5 solution (20 µL, 10 mg/L) and diluted with 0.1 % formic acid in deionised water 
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(1.5 mL) directly into 96-well plates. Two injections were made from each well (one from 
each autosampler needle).  
Analysis was carried out using a 1290 Infinity II™ LC system coupled with an Ultivo™ triple 
quadrupole mass-spectrometer (both Agilent Technologies, Santa Clara, CA, USA). 
Prepared samples (2 µL) were injected using a dual-needle autosampler onto a Raptor™ 
biphenyl column (5.0 x 3.0 mm, 2.7 µm, Thames Restek, High Wycombe, UK) fitted directly 
to the MS ionisation source to permit rapid gradient analysis 26. LC parameters are 
summarised in Table S1. Ionisation source conditions were: sheath gas temperature 
350 C, sheath gas flow-rate 9 L/min, nebulizer 55 psi, drying gas temperature 350 C, 
drying gas flow-rate 11 L/min, capillary voltage 2.5 kV. Ion transitions (collision energy, V) 
were: m/z 194.1 to 104.9 (17) and 163.0 (5), and 199.2 to 107.0 (21) and 165.0 (5) for 
MDMA and MDMA-D5, respectively. The dwell time for each MRM transition was 10 ms, 
and the accelerator voltage was 9 V. 
2.5 DATA PROCESSING 
Unlike pharmaceutical dissolution testing, in which all tablets are expected to contain the 
same dose of active pharmaceutical ingredient, the MDMA content of each tablet was 
unknown prior to analysis. Dissolution profiles were plotted as (i) concentration (mg/L) 
versus time and (ii) percent dissolved (relative to the 180-minute time point) versus time. 
Statistical comparisons were made using One Way Analysis of Variance carried out using 
Minitab® (version 18) and illustrated using Microsoft Excel (2016 version). For all 
calculations, MDMA was measured as free-base rather than the hydrochloride salt.  
3 RESULTS 
3.1 MDMA CONTENT 
Calibration was linear over the range 0.50 – 100 mg/L (typical r2 > 0.9984). The within-
batch imprecision (% CV) for the three IQC tablets (initial measured MDMA content 134, 
71 and 34 mg free-base) was < 13.3 % for each of the five batches, and the between-batch 
imprecision was < 11.8 %. Comparison of the EQC sample results (N = 10 tablets, MDMA 
content range 9 – 134 mg by the in-house method) showed excellent agreement (y = 
1.0241x – 1.1456, r2 = 0.9956). EQC results demonstrating our method accuracy are 
summarised in Figure S1. The stability of MDMA in the dissolution solution at 37 C for 
the 180-minute duration of the experiment, was 98.0 ± 1.5 %. 
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For the tablets used to investigate MDMA content (N = 412), the median MDMA content 
tended to decrease overall between 2001 and 2009, but then increased from 2010 
onwards (Figure 1). It should be noted that the number of tablets available for this study 
from 2009, 2010 and 2012 was low, 4, 2 and 6, respectively. This was attributed to the 
low purity and availability of MDMA-containing ecstasy during these years, and the 
increase in availability of then-legal novel psychoactive substances. That said, there was 
a statistically significant difference (p < 0.001) in MDMA content for those tablets 
collected pre-2010, and those collected post-2010 (Figure 2).  
<<Figures 1-2 here>> 
The median (range) MDMA content per tablet, tablet mass (mg) and MDMA content 
expressed as a percentage of the tablet mass by year is summarised in Table 1. There was 
only a weak correlation between total tablet mass and MDMA content (r2 = 0.2919, Figure 
S2). Overall, the median tablet mass increased over the period studied (Figure 1).  
<<Table 1 here>> 
The within-batch MDMA content and tablet mass variability (N = 45 batches of tablets) 
are summarised in Figure S3, ordered by year. The median (mean, range) difference in 
tablet mass (heaviest minus lightest tablet) within a batch was 5 (14, 0 – 80) mg. The 
median (mean, range) content difference (highest minus lowest MDMA content) was 10 
(19.5, 2.2 – 136) mg. The mean within-batch precision in MDMA content (% CV) was 
16.4 %. Twenty two (49 %) of the batches had a within-batch precision less than 10 %. 
Of the tablets tested which were expected to contain additional, non-MDMA, compounds, 
22 (65 %) were found to contain caffeine. Other compounds identified (number of tablets) 
were: amfetamine (1), metamfetamine (1), 3,4-methylenedioxyethylamfetamine (MDEA) 
(3), cocaine (1), ketamine (3), methylephedrine (1), phentermine (1), 1-benzylpiperazine 
(BZP) (6), 1,4-dibenzylpiperazine (DBZP) (6), meta-chlorophenylpiperazine (mCPP) (3), 
diphenhydramine (2), and N,N-diallyl-5-methoxy-tryptamine (5-MeO-DALT) (1). From the 
visual identification made by TICTAC, two tablets were expected to contain methylone, in 
addition to MDMA, but were found to contain MDMA only. MDMA content of those with 
additional compounds was significantly lower than the MDMA-only tablets (p < 0.001).  
3.2 DISSOLUTION 
Calibration curves were fitted with a quadratic curve (weighted by the reciprocal of x2, 
not forced through the origin) over the concentration range 0.1 – 200 mg/L (typical r2 > 
0.9998). The within-batch and between-batch (N = 9 batches) precisions for the three 
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independently-prepared IQC solutions were all < 13.7 % and < 13.8 %, respectively. Mean 
within-batch accuracy (% nominal concentration, N = 30 replicates of each IQC) was 92-
96 %, and the mean between-batch accuracy (N = 9 batches) was 106 – 116 %.    
The MDMA tablets were expected to be immediate release formulations and the 
180-minute time point was chosen pragmatically as the time when dissolution was 
complete. Inspection of the dissolution curves showed plateaus of relative concentration 
confirming this expectation. Using data from the 180-minute time point, accounting for 
the dissolution vessel volume of 900 mL, and assuming complete dissolution at the 180-
minute time point, the MDMA content of each of the tablets included in the dissolution 
experiment was calculated.  
Data from 247 dissolution experiments were included in the analysis. The median (25th 
and 75th percentiles) data from each time point were plotted to produce dissolution 
profiles, using both MDMA concentration (mg/L) versus time, and percent dissolved 
versus time. Assuming complete dissolution at 180 minutes, the concentration at this 
time point gave another measure of MDMA content and provided further data for the 
variability in MDMA content of the tablets tested; median (range) MDMA content 70 mg 
(7 – 182 mg) free-base after accounting for dissolution vessel volume.  
The distribution of the percent released was examined for each time point. Analysis of 
data at the 15-minute and 30-minute time points revealed a tri-modal distribution at 15 
minutes, and a bi-modal distribution at 30 minutes. These were confirmed by analysis of 
variance (p < 0.001) which showed three distinct groups based on the percent dissolved 
at 15 minutes; mean (95% CI) percent dissolved: fast-releasing 95.0 % (93.4 – 96.6 %), 
intermediate-releasing 68.4 % (66.5 – 70.3%), and slow-releasing 39.4 % (37.7 – 41.1 %) - 
Figure 3A - and two distinct groups at 30 minutes: fast-releasing 95.7 % (94.4 – 97.1 %) 
and slow-releasing 57.3 % (55.2 – 59.3 %) - Figure 3B. Using these distribution data, tablets 
were then classified for each of the two time points into (i) slow-releasing ( 54 % 
dissolved), (ii) intermediate-releasing (55 – 81 % dissolved), or (iii) fast-releasing (≥ 81 % 
dissolved) for the 15-minute time point, and as (i) slow-releasing (< 77 % dissolved) or (ii) 
fast-releasing (≥ 77 % dissolved) for the 30-minute time point. Dissolution profiles 
produced for each tablet class using the median (25th and 75th percentiles) percent 
dissolved at each time point are shown in Figure 4. At the 15-minute time point, there 
were 95 (38 %) fast-releasing tablets, 67 (27 %) intermediate-releasing tablets, and 85 
(35 %) slow-releasing tablets. At the 30-minute time point, there were 172 (69 %) fast-
releasing tablets and 75 (31 %) slow-releasing tablets. The highest content slow-releasing 
tablet (based on the 15-minute time point) contained 156 mg MDMA free-base (185 mg 
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MDMA HCl). All MDMA crystal samples, including those wrapped in ‘bombs’, were 
classified as fast-releasing at both time points. There were no statistically significant 
differences in MDMA content based on dissolution classification at either 15-miute (p = 
0.527) or 30-minute (p = 0.067) time points (Figure 5). Furthermore, dissolution 
classification was not always consistent within the batch of tablets. At the 30-minute time 
point, there was discrepant classification (that is, at least one tablet in the batch was 
classified differently to the remainder) in 10 (16 %) of the batches tested (for example, 
Batch 89, N = 5 tablets, contained two fast-releasing and three slow-releasing tablets). 
<<Figures 3-5 here>> 
The proportion of fast-releasing, intermediate-releasing, and slow-releasing tablets by 
year is shown in Figure 6. Overall, the proportion of slow-releasing tablets decreased 
(64.3 % of tablets 2001 – 2003 to 17.0 % of tablets 2016 – 2018), and the proportion of 
fast-releasing tablets increased from 21.4 % of tablets 2001 – 2003 to 52.3 % of tablets 
2016 – 2018 over the period studied, but there was still significant between-tablet 
variability in dissolution in each year group. 
<<Figure 6 here>> 
3.3 TABLET CHARACTERISTICS – CORRELATION WITH MDMA CONTENT AND 
DISSOLUTION. 
With few exceptions (for example a batch of heart-shaped tablets in 2005), round/circular 
tablets were predominant until 2010. Thereafter, more elaborate-shaped tablets became 
more common. Likewise, prior to 2010, the majority of tablets were white in colour, after 
which more colourful, and even multi-coloured tablets became more common (Figure 7). 
Statistically, white tablets and round tablets contained significantly less MDMA than the 
remainder of the tablets tested (both p < 0.001). There was no association (Chi-squared 
test) between the white/non-white tablets and the dissolution classification at either 15-
minutes (p = 0.272) or 30 minutes (p = 0.729), nor between the round/non-round tablets 
and dissolution classification at either time point (p = 0.055 and 0.246 at 15-minutes and 
30-minutes, respectively).   
<<Figure 7 here>> 
4 DISCUSSION 
Previous studies have highlighted the risk of variability in MDMA content of ecstasy 
tablets9,27. Furthermore, a number of studies have suggested that in recent years, the 
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amount of MDMA in tablets is increasing9. Data from the UK presented from the MDMA 
content measurement portion of this study support these observations (Figure 8)24. Our 
data from 2006 showed the highest content tablet contained 110 mg MDMA free-base 
(131 mg MDMA HCl)21. However, in 2018, the median MDMA content exceeded 100 mg 
(equivalent to 118 mg MDMA hydrochloride) for the first time, and the highest content 
tablet contained 241 mg MDMA free-base (286 mg MDMA HCl), more than double the 
content of the highest of the 2006 tablets (Table 1). We observed a statistically 
significantly lower MDMA content for white and for round tablets, though this can be 
explained by the fact that these tablets tended to be from earlier years, when MDMA 
content was lower (Figure 1). That said, white, round tablets should not universally be 
considered ‘low-dose’ – one such tablet from 2001 had an MDMA content of 184 mg free-
base (219 mg MDMA HCl). Two tablets from a batch which were labelled with ‘199.9 mg’ 
(presumably to reflect the apparent MDMA ‘dose’) were in fact found to contain 78.3 and 
90.0 mg MDMA free-base (Figure 7). 
<<Figure 8 here>> 
The samples collected and used for this study provided the opportunity to investigate the 
variability in MDMA content within batches of tablets. Though for many of the batches 
tested the number of tablets was low (minimum 2 tablets per batch), the data revealed 
that the within-batch reproducibility of tablet mass was generally good. This is likely a 
reflection of the reproducibility of modern tablet-pressing equipment9. However, some 
batches showed large differences, even in the mass of tablets. One batch (Batch 14, N = 
4) showed a difference of 80 mg between the heaviest and lightest tablet in the batch 
(MDMA content of the heaviest and lightest tablets in this batch 46 and 22 mg MDMA 
free-base, respectively).  
With respect to MDMA content of tablets within batches, there was greater variability 
than in the tablet mass (median difference in MDMA content 10 mg). Almost half the 
batches tested showed ‘good’ tablet-to-tablet reproducibility (% CV < 10 %). However, a 
number of batches showed marked differences in MDMA content despite similar tablet 
mass. For example, in one batch (Batch 1, N = 4 tablets), despite all tablets being very 
similar in mass (range 256-259 mg), significant variability in content was observed (range 
70-184 mg MDMA free-base). When producing tablets in the pharmaceutical industry, 
homogeneity of the bulk powder using high-shear mixing tools is essential to ensure 
content uniformity of the active pharmaceutical ingredient, and forms an integral part of 
release-testing protocols28. Variability in MDMA content within a batch of illicit tablets, 
when the tablet mass is consistent, most likely represents incomplete mixing of the 
MDMA and tablet excipients prior to pressing and of course demonstrates the inevitable 
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lack of quality control for illicitly produced tablets. For MDMA users, our data suggest that 
analysis of a single tablet from a batch cannot guarantee that all others in the same batch 
are of the same content. For users tending to base their tablet ingestion (i.e. the number 
of tablets) on previous experiences, this could prove dangerous. For instance, a user may 
be ‘accustomed’ to taking 200 mg MDMA per night. If they are informed upon analysis 
that a batch of tablets each contain 50 mg MDMA, then they will plan to ingest four 
tablets from that batch. In reality, content variability of MDMA tablets may mean that, in 
total, they far exceed this dose, and hence increase their risk of toxicity. 
LC-MS/MS was chosen as the analytical method for these studies for a number of reasons. 
Primarily, the specificity of mass-spectrometry when compared to the more normal UV 
detection allowed for the analysis of tablets with unknown excipients, contaminants, or 
adulterants which may interfere in UV systems. In addition, LC-MS/MS allowed for the 
inclusion of isotopically-labelled MDMA as an internal standard for quantitation. Finally, 
for the dissolution experiments in particular, where the number of samples to be analysed 
was large, ultra-rapid, high-throughput analysis was permitted (36 s per injection). 
Measurement of MDMA content is useful for implementing harm-reduction strategies 
and providing information on trends for both MDMA users and healthcare professionals. 
Typically, as in the first part of this study, these data are presented as retrospective audits 
of substances collected or purchased over a number of years, carried out in laboratory 
settings by groups such as the Drug Information and Monitoring System (DIMS) in the 
Netherlands, which has been in existence since 199229,30 and the National Detection 
System of Drugs and Toxic Substances (SINTES) in France13. Some laboratory-based 
groups, e.g. DanceSafe in the United States and Canada, and most recently the Welsh 
Emerging Drugs and Identification of Novel Substances (WEDINOS) Project in Wales and 
the UK publish their analytical findings online31-33. A review of the analytical techniques 
used in European testing laboratories was compiled as part of the Trans-European Drug 
Information (TEDI) project20,34. 
Non-laboratory-based (‘in-field’ or mobile) testing of MDMA and other substances is also 
commonly carried out, for instance at music festivals, nightclubs, and in city-centres, with 
the aim of rapidly informing users of risk(s), e.g. due to circulation of high-content tablets, 
and in efforts to reduce harm. A number of organisations, including some already 
mentioned that also offer laboratory-based testing, carry out such testing services, e.g. 
Check It! (Austria), Check !n (Portugal), Energy Control (Spain), Safer Dance (Switzerland) 
and The Loop (UK)30. Field-based drug identification tends to be limited to colourimetric 
reagent tests, spectroscopic methods, e.g. infra-red (IR), Fourier transform IR (FTIR) and 
Raman spectroscopy, and occasionally thin layer chromatography. Whilst these methods 
Variability in dissolution profiles of MDMA tablets 
Couchman L, et al 
Page 13 of 18 
are cheap, rapid, and easily carried out without the need for elaborate laboratory 
infrastructure, colourimetric reagent tests are highly subjective, and there are limitations 
of spectroscopic methods in both sensitivity and specificity (particularly for tablets and 
powders containing mixtures of compounds or for very low concentration 
adulterants)20,35-37. Further, the results produced by spectroscopic methods are 
dependent on (i) up-to-date libraries to include the latest substances, and (ii) complex in-
built identification algorithms for the analysis of mixtures. For the latter, such libraries are 
now available, and are ever-growing to include new compounds, e.g. TICTAC spectral 
libraries for novel psychoactive substances38. Mobile HPLC with ultraviolet and MS 
detection (single quadrupole) has also been used by the Check It! organisation in Austria, 
with throughput of approximately 40 samples per hour, using a modified laboratory van 
which can be deployed to music festivals. The LC-MS/MS method used for the dissolution 
profiling in this study provides additional evidence that, although significantly more 
expensive than colourimetric and spectroscopic methods, these specific and sensitive 
methods can in fact be carried out very rapidly (up to one 96-well plate per hour 
throughput using the method described). Through implementing novel, miniaturised 
instrumentation, such as the triple quadrupole MS used for the dissolution analyses in 
this study (Ultivo™), these techniques are also becoming more amenable to non-
laboratory environments. 
Most importantly, the data in the second part of this study showed significant differences 
in the dissolution profile of MDMA tablets. These data highlight an extremely important 
additional risk with regards variability in MDMA tablets. There is little doubt that higher-
content MDMA tablets pose a greater risk of toxicity to users than low-content 
tablets27,39,40. Content variability aside, risks for fast-releasing and slow-releasing tablets 
should also be considered, especially since our data suggest no definite way to know a 
priori which class a tablet is likely to be in (e.g. based on colour or shape), and there were 
no statistically significant differences in MDMA content for fast-releasing, intermediate-
releasing, or slow-releasing tablets. For high-content tablets, if the tablets are fast-
releasing, toxicity may manifest rapidly (within 15 minutes or less) and hence will require 
rapid emergency treatment in cases of overdose. However, the highest risk could be 
posed by high-content, slow-releasing tablets. Peak plasma concentrations following oral 
administration of these tablets may be some hours after ingestion based on dissolution 
data from this study. For these tablets, users expecting a ‘high’ 15-30 minutes after 
ingestion may re-dose before peak concentrations for the first tablet have been reached, 
exacerbating any toxicity41. Healthcare workers should be aware that high-content, slow-
releasing tablets are in circulation, and that users presenting with MDMA toxicity may not 
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have reached peak plasma concentrations if they have ingested (multiple) slow-release 
tablets.   
These data also impose an inherent limitation for rapid MDMA analysis. Whilst 
identification and content measurements can be made quickly and in remote locations, 
to assess dissolution profiles takes a much longer time (180 minutes using the method 
described, plus analysis time thereafter), and requires additional specialist equipment in 
a laboratory setting.  
Knowledge of the MDMA content alone does not fully assess the risk for a tablet, or batch 
of tablets. The dissolution studies were conducted in standard aqueous buffer at acidic 
pH and whilst the findings of this study illustrate the potential variability in release rates 
from the tablets analysed, it should be noted that the in vitro – in vivo correlation of these 
data to predict physiological outcomes has not been confirmed.  Further work would be 
needed in order to obtain this evidence. At present, there is no correlation with other 
tablet characteristics or parameters to identify fast- and slow-releasing tablets. In this 
work, we did not carry out any further tablet characterisation experiments (e.g. 
assessment of tablet hardness or friability) to correlate to dissolution, nor did we assess 
dissolution of any crushed tablets. Although the tablets were stored in dark, dry 
conditions and room temperature, we cannot be certain that storage did not have a 
detrimental effect on content. Finally, our data do not account for the inherent risk of 
illicitly manufactured drugs from non-pharmaceutical excipients, e.g. heavy metals, which 
should not be overlooked42. The nature of these and other diluents (often sugars such as 
lactose) needs to be explored.  
5 CONCLUSIONS 
Recreational MDMA use continues to be widespread. Recent concerns have focussed on 
the prevalence of high-content MDMA tablets in circulation, and our data from the UK 
support these observations.  
However, in addition, we have demonstrated that variability in dissolution profiles of 
MDMA tablets must be considered. Rapid drug identification and quantitation are useful 
and transferable to non-laboratory settings, but in the light of these new data, do not and 
cannot fully-assess the risk to users due to the presence of fast- and slow-releasing MDMA 
tablets on the illicit market.  
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